User profiles for Medha Barbhaiya
Medha BarbhaiyaAssistant Professor at Hospital for Special Surgery and Weill Cornell Medicine Verified email at hss.edu Cited by 3631 |
The 2023 ACR/EULAR antiphospholipid syndrome classification criteria
M Barbhaiya, S Zuily, R Naden, A Hendry… - Arthritis & …, 2023 - Wiley Online Library
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …
specificity for use in observational studies and trials, jointly supported by the American …
2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases
…, CW White, J Yazdany, M Barbhaiya… - Arthritis & …, 2020 - Wiley Online Library
Objective To develop an evidence‐based guideline on contraception, assisted reproductive
technologies ( ART ), fertility preservation with gonadotoxic therapy, use of menopausal …
technologies ( ART ), fertility preservation with gonadotoxic therapy, use of menopausal …
Understanding the role of environmental factors in the development of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multisystem disease with a complex etiology. Its
risk is higher among women, racial and ethnic minorities, and individuals with a family history …
risk is higher among women, racial and ethnic minorities, and individuals with a family history …
Environmental exposures and the development of systemic lupus erythematosus
M Barbhaiya, KH Costenbader - Current opinion in rheumatology, 2016 - journals.lww.com
… Barbhaiya, Medha; Costenbader, Karen H. … Correspondence to Medha Barbhaiya, MD,
MPH, Division of Rheumatology, Immunology and Allergy, Department of Medicine …
MPH, Division of Rheumatology, Immunology and Allergy, Department of Medicine …
Adverse effects of low-dose methotrexate: a randomized trial
…, J Colls, C Xu, J MacFadyen, M Barbhaiya… - Annals of internal …, 2020 - acpjournals.org
Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic
rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid …
rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid …
Racial/ethnic variation in all‐cause mortality among United States Medicaid recipients with systemic lupus erythematosus: a Hispanic and Asian paradox
JA Gómez‐Puerta, M Barbhaiya, H Guan… - Arthritis & …, 2015 - Wiley Online Library
Objective The incidence of systemic lupus erythematosus (SLE) is disproportionately high in
nonwhite patients compared with white patients. However, variation in mortality according to …
nonwhite patients compared with white patients. However, variation in mortality according to …
Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria
Objective An international multidisciplinary initiative, jointly supported by the American College
of Rheumatology and European Alliance of Associations for Rheumatology, is underway …
of Rheumatology and European Alliance of Associations for Rheumatology, is underway …
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
M Barbhaiya, JM Levine, VP Bykerk… - Annals of the …, 2021 - ard.bmj.com
Supplemental material This content has been supplied by the author (s). It has not been
vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any …
vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any …
Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts
M Barbhaiya, SK Tedeschi, B Lu, S Malspeis… - Annals of the …, 2018 - ard.bmj.com
Objectives Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease,
subtyped according to clinical manifestations and autoantibodies. Evidence concerning …
subtyped according to clinical manifestations and autoantibodies. Evidence concerning …
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort
…, A Banzato, E Sevim, M Barbhaiya… - Seminars in arthritis and …, 2019 - Elsevier
Objectives To assess whether patients with antiphospholipid syndrome (APS) and history of
recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome …
recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome …